Takeda

We’re proud to present new interim data for primary immunoglobulin A (IgA) nephropathy at this year’s #KidneyWk. As a leading cause of chronic kidney disease and kidney failure, IgA nephropathy remains a critical focus of kidney research. Read more here: https://lnkd.in/eXGPcchK

Primary IgA nephropathy is a lifelong progressive autoimmune disease often diagnosed in young people aged 10-30 years old that may cause irreversible damage to the kidney function. For people living with IgA nephropathy, symptoms vary and may not appear for years or decades. Hear from Stuart whose symptoms started at 25 years old – years before his official diagnosis – underscoring the importance for greater disease awareness and education.

Integrity, fairness, honesty and perseverance aren’t just words on a wall. They guide decisions, shape culture and keep us focused on what matters most: doing the right thing for patients and each other. We’re ready to collaborate, grow and make history. Are you? Explore open roles: https://bit.ly/3WG7nj5 #TeamTakeda #MakeHistoryChangeFutures #BioPharmaHiring #ValuesDriven

Alpha-1 antitrypsin deficiency (AATD) can cause silent damage in the liver and have a significant impact on patients when diagnosis is delayed or mistaken for another chronic liver disease. We’re committed to advancing research to address the unmet needs of the AATD-associated #LiverDisease community. This year at The Liver Meeting, we’re presenting data that can build understanding of liver transcriptomic signatures, liver disease progression, non-invasive tests and AI-driven digital pathology approaches in clinical development. #TLM25 Intended only for health care professionals.

Primary Immunodeficiencies (PIDs) are a group of conditions that make it difficult for the body to fight infections. About 70-90% of people living with PID worldwide remain undiagnosed, largely due to a lack of awareness among patients and physicians. At this year’s International Primary Immunodeficiencies Congress (#IPIC2025), we hope you’ll stop by our booth to learn more about PID as well as our advocacy partner IPOPI's booth. Together with IPOPI, we are dedicated to raising awareness and driving meaningful conversations about PID. #PatientCentricCare #PlasmaDerivedTherapy #PID #IPIC2025

Last week at #ACR25, we had the privilege of connecting with leading rheumatologists and sharing our latest research on the TYK2 pathway and psoriatic arthritis (PsA)-related biomarkers. PsA diagnosis is often delayed due to the various ways that it presents in patients – emphasizing the importance of continued biomarker research. We are committed to driving research that has the potential to improve both short- and long-term outcomes for the PsA community.

Science is moving forward—so are we. This year, we’re proud to present research in #HereditaryAngioedema (#HAE) and eosinophilic esophagitis (#EoE) and exchange perspectives to help advance care in #PrimaryImmunodeficiency at the American College of Allergy, Asthma and Immunology (ACAAI) 2025 Annual Scientific Meeting. These are areas where significant unmet needs persist, and evidence generation has the potential to make a meaningful difference for individuals living with rare and complex immunological conditions. Join us at booth #802 to connect with our team. Learn more about our commitment to #RareDisease: https://lnkd.in/evaPxzr3 #ACAAI25

At this year’s International Primary Immunodeficiencies Congress (#IPIC2025), we are proud to drive conversation around mastering the art of patient-centric care during our breakfast symposium on November 6. Join our esteemed panel of experts for a thoughtful discussion on advancing patient care and strategies for treatment across diverse patient populations. #PatientCenteredCare #PlasmaDerivedTherapies #BreakfastSymposium #IPIC2025

We're thrilled to share our latest research at the upcoming 67th American Society of Hematology's Annual Meeting. Our diverse portfolio will feature more than twenty-five presentations, focusing on new clinical data in hematologic cancers and bleeding disorders. Learn more: https://lnkd.in/efpYNSrn

Career development is no longer a linear path—and that’s exactly why we built our AI-enabled platform, Career Navigator.  Marlucy Spencer, Takeda Business Solutions Capabilities Lead, has embraced this tool to take a proactive approach to her learning and growth—leveraging its insights and opportunities to shape her career with confidence.  See how we’re helping employees grow with purpose by providing personalized ways to discover roles, learn and connect: https://bit.ly/48VeNWX #MakeHistoryChangeFutures #TeamTakeda #CareerGrowth #ProfessonalDevelopment